- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Alex Moulson on How Companies Choose Which Biosimilars to Produce
We sat down with Alexandra Moulson, vice president of Strategy, Programs, and Portfolio at Polpharma Biologics to discuss how Polpharma Biologics and other contract development and manufacturing organization (CDMOs) function and how companies choose which molecules to develop.
Being based in Europe can have unique challenges for a company like Polpharma Biologics, a contract development and manufacturing organization (CDMO) with facilities in Poland and the Netherlands that specializes in biologics. Despite facing hurdles such as navigating partnerships to commercialize in multiple markets, developing complex molecules for international partners, and figuring out how to handle coronavirus disease 2019 (COVID-19) with facilities in 2 countries, Polpharma Biologics has grown to become a powerhouse, having 7 biosimilars in its pipeline and partnerships with Sandoz and Bioeq.
We sat down with Alexandra Moulson, vice president of Strategy, Programs, and Portfolio at Polpharma Biologics to discuss how Polpharma Biologics and other CDMOs function and how companies choose which molecules to develop.
To check out more of our coverage of Polpharma Biologics, click here.
To learn more about Polpharma's natalizumab clinical trial, click here.
To learn about Polpharma Biologics recent integration efforts, click here.
To learn more about Polpharma Biologics, click here.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
